Novel agents that target tublin and related elements

Abstract

The success of the taxanes and other agents that target tubulin and mitosis and their evolution to being mainstay constituents of both curative and palliative therapeutic regimens for a wide variety of malignancies have amplified efforts to discover anti-mitotic and anti-microtubule agents with greater therapeutic indices. A wide variety of structurally diverse compounds that have demonstrated broad and potent anti-tumor activity in preclinical evaluations are currently being evaluated in clinical investigations. This review will discuss the characteristics of novel taxanes and other agents that might confer clinical advantages relative to the anti-tubulin and anti-mitotic agents in clinical use. Besides taxanes with novel delivery systems and unique physicochemical characteristics, the epothilones and other natural products, as well as developmental therapeutics against new mitotic targets, will be reviewed.